Login / Signup

C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.

Saif AhmadChirayu PandyaAdam KindelinKanchan BhatiaRafay ChaudharyAlok Kumar DwivediJennifer M EschbacherQiang LiuMichael F WatersMd Nasrul HodaAndrew F Ducruet
Published in: British journal of pharmacology (2020)
We conclude that SB290157 is safe and effective with and without late IVT following TE stroke. Therefore, C3a receptor antagonist therapy represents a promising candidate for clinical translation in stroke, particularly as an adjuvant to IVT.
Keyphrases
  • atrial fibrillation
  • early stage
  • cerebral ischemia
  • acute ischemic stroke
  • mesenchymal stem cells
  • bone marrow
  • cell therapy
  • smoking cessation